Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01047397 | Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia | PHASE2 | COMPLETED | 107 | — | — | Mar 1, 2010 | Feb 1, 2011 | Nov 11, 2013 | 37 | Australia, India +2 |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Active Drug |
| Group 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| 1278863A | DRUG | 25mg, 50mg, 100mg |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: 1. Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent. 2. A male or female is eligible to enroll and participate in this study if he/she: 1. (Part 1) has Moderate to Severe Renal Impairment (equivalent to NKF KDOQI Stage 3 or...